Mandate

Vinge advises Axcel on its acquisition of Loopia and Active 24 from Visma

June 19, 2018 M&A

Vinge has advised the Nordic private equity firm Axcel on its acquisition of Visma’s hosting business, operating under the brands Loopia and Active 24.

Loopia and Active 24 are leading mass hosting providers and offer web domains, shared web hosting and value-added services such as security, e-commerce and Microsoft Office 365. The products are sold online on a prepaid subscription basis to around 350,000 SMEs and prosumer customers across primarily Sweden and the Czech Republic, with a further presence in Germany, Norway, the Netherlands, Serbia, Slovakia, Spain and the UK.
 
Vinge’s team consisted of partners Christina Kokko (M&A), Mikael Ståhl (Banking and Finance) and Eva Fredrikson (Commercial Agreements) together with associates Linda Sengul, Karl Klackenberg and Martin Cronsioe (M&A), Emelie Klefbeck, Josefine Larsson (Banking and Finance), Christoffer Nordin, Mathilda Persson, Isabell Nielsen, Jasmin Draszka-Ali, Lisa Hörnqvist, Moa Bodin (Commercial Agreements), Klara Secher (IP), Lova Unge, Sophia Holm (Employment), Kristoffer Larson (Real Estate), Daniel Wendelsson, Johan Wahlbom (Competition), Boris Kotur and Edin Agic (Corporate) and VDR assistant Jessica Öijer.
 

Related

Vinge advises OsteoCentric on the public offer for Integrum

OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025